osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
ln the adaura primary analysis, adjuvant osimertinib demonstrated a stafistically significant and clinically meaningful dfs beneft vs placebo in resected egfrm stage ib-iiia nsclc, along with improved cns dfs and a tolerable safety profile #asco2023 #asco23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.